COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Versartis Long-Acting Growth Hormone in Children Compared to Daily rhGH (VELOCITY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02339090
Recruitment Status : Completed
First Posted : January 15, 2015
Last Update Posted : March 8, 2018
Information provided by (Responsible Party):
Versartis Inc.

Brief Summary:
The trial will compare a twice-monthly somavaratan dosing regimen for non-inferiority of treatment effect against daily injections of rhGH.

Condition or disease Intervention/treatment Phase
Growth Disorders Drug: somavaratan Drug: Daily rhGH Phase 3

Detailed Description:
This study is designed as a pivotal study to compare the safety and efficacy of a selected dose regimen of somavaratan to daily rhGH. The study is a randomized, multi-center, open label study of 12 months duration. The primary endpoint is height velocity at 12 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 136 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison of Somavaratan (VRS-317), a Long-acting Human Growth Hormone, to Daily rhGH in a Phase 3, Randomized, One-year, Open-label, Multi-center, Non-inferiority Trial in Pre-pubertal Children With Growth Hormone Deficiency.
Actual Study Start Date : August 24, 2015
Actual Primary Completion Date : August 23, 2017
Actual Study Completion Date : August 23, 2017

Arm Intervention/treatment
Experimental: somavaratan
somavaratan long acting recombinant human growth hormone administered subcutaneously twice-monthly
Drug: somavaratan
long acting growth hormone therapy
Other Name: Long acting recombinant human growth hormone

Active Comparator: Daily rhGH
Daily recombinant growth hormone therapy administered subcutaneously every day
Drug: Daily rhGH
daily growth hormone therapy
Other Names:
  • daily growth hormone
  • recombinant growth hormone therapy

Primary Outcome Measures :
  1. Efficacy (Annual height velocity) [ Time Frame: 12 months ]
    Annual height velocity

Secondary Outcome Measures :
  1. Pharmacodynamics (IGF-I and IGFBP-3 responses to study drug administration) [ Time Frame: 12 months ]
    IGF-I and IGFBP-3 responses to study drug administration

  2. Safety as measured by he number of patients with adverse events, concomitant medications, safety labs, vital signs, physical exams, and repeat dose immunogenicity. [ Time Frame: 12 Months ]
    Safety observations will include the number of patients with adverse events, concomitant medications, safety labs, vital signs, physical exams, and repeat dose immunogenicity.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   3 Years to 11 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Chronological Age ≥ 3.0 years and ≤ 10.0 (girls) and ≤ 11.0 (boys).
  • Pre-pubertal status: Absent breast development in girls, testicular volume < 4.0 mL in boys.
  • Diagnosis of GHD as documented by two or more GH stimulation test results ≤ 10.0 ng/mL.
  • Height SD score ≤ -2.0 at screening.
  • Weight for Stature ≥ 10th percentile.
  • IGF-I SD score ≤ -1.0 at screening.
  • Delayed bone age (≥ 6 months).

Exclusion Criteria:

  • Prior treatment with any growth promoting agent
  • History of or concurrent significant disease (e.g. diabetes, cystic fibrosis, renal insufficiency).
  • Chromosomal aneuploidy, significant gene mutations (other than those that cause GHD) or confirmed diagnosis of a named syndrome.
  • A diagnosis of Attention Deficit Hyperactivity Disorder.
  • Daily use of anti-inflammatory doses of glucocorticoid.
  • Prior history of leukemia, lymphoma, sarcoma or cancer.
  • Treatment with an investigational drug in the 30 days prior to screening.
  • Known allergy to constituents of the study drug formulation.
  • Ocular findings suggestive of increased intracranial pressure and/or retinopathy at screening.
  • Significant spinal abnormalities including scoliosis, kyphosis and spina bifida variants.
  • Significant abnormality in screening laboratory studies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02339090

Sponsors and Collaborators
Versartis Inc.
Layout table for investigator information
Study Director: Will Charlton, MD Sponsor GmbH
Layout table for additonal information
Responsible Party: Versartis Inc. Identifier: NCT02339090    
Other Study ID Numbers: 14VR4
First Posted: January 15, 2015    Key Record Dates
Last Update Posted: March 8, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Versartis Inc.:
Growth Hormone Deficiency
Long Acting Recombinant Growth Hormone
Long Acting Growth Hormone
Pediatric Growth Hormone Deficiency
Growth Hormone Replacement Therapy
Human Growth Hormone
growth failure
Additional relevant MeSH terms:
Layout table for MeSH terms
Growth Disorders
Pathologic Processes
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs